ACHN’s 4-week data for ACH-1625 are not especially noteworthy one way or the other, IMO.
I'd say that's true with respect to the efficacy data. (It is good that the 200mg QD dose performed as well as the higher doses so it looks like they can move forward with that low dose.) I think it is at least somewhat noteworthy that they passed the safety hurdle, although the big test will come at the end of the year when 3-month data is announced. Of course, I'm not surprised the stock barely budged as it had already run up nicely from $5 to $7. ACHN would be wise to do a nice offering soon and take advantage of the share price appreciation to really extend their runway and strengthen their position at the bargaining table for a partnership for 1625 and the other HCV candidates. I will continue to look towards just after the 3-month data is announced at year end as a possible entry point (assuming positive results, valuation around current level or preferably lower, and ACHN having done a nice raise). I still think that if they're going to land a nice deal for 1625, or get a possible buyout offer, it's likely going to occur at that point.
Market Data 
Markets 
AI
